[Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review].
T Yu DemidovaV V TitovaM Y IzmaylovaPublished in: Terapevticheskii arkhiv (2023)
Glucagon-like peptide-1 receptor agonists (arGLP1) are an effective treatment for patients with type 2 diabetes mellitus (T2DM), mainly due to increasing insulin secretion and suppressing glucagon release by stimulating the respective receptors. Taking into account their positive effect on major cardiovascular events, drugs in this group with proven cardioprotective effects are recommended for patients with T2DM and clinical cardiovascular diseases or multiple cardiovascular risk factors. In this paper, we present an overview of current clinical studies on the clinical efficacy and safety of arGLP1 and discuss current prospects for arGLP1 as a therapy for patients with T2DM.
Keyphrases
- cardiovascular risk factors
- cardiovascular events
- cardiovascular disease
- end stage renal disease
- coronary artery disease
- ejection fraction
- chronic kidney disease
- metabolic syndrome
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- type diabetes
- patient reported outcomes
- skeletal muscle
- current status
- adipose tissue